The pocket proteins retinoblastoma protein (pRb), p107 and p130 are the key targets of oncoproteins expressed by DNA tumor viruses. Some of these viral proteins contain an LXCXE motif that mediates the interaction with the three pocket proteins and the inhibition of the pRb SUMOylation. Kaposi's sarcoma herpesvirus (KSHV) contains at least two proteins that can regulate pRb function but, so far, a KSHV-encoded protein targeting p107 and p130 has not been identified. Here, we show that the KSHV latent protein LANA2 binds to pRb, p107 and p130. LANA2 contains an LXCXE motif that is required for bypassing pRb-mediated cell-cycle arrest and for inhibiting pRb SUMOylation. Finally, we demonstrate that, in addition to pRb, both p107 and p130 can be SUMOylated, and this modification is also inhibited by LANA2 in an LXCXE-dependent manner. These results demonstrate, for the first time, the SUMOylation of p107 or p130 and, so far, they represent the first example of a KSHV protein able to interact with the three pocket proteins and to inhibit their conjugation to SUMO.
INTRODUCTION
The retinoblastoma protein (pRb) family is constituted by pRb, p107 and p130. [1] [2] [3] [4] The three proteins show maximal identity in the conserved pocket region, through which pRb, p107 and p130 interact with viral oncoproteins and cellular factors, such as the E2F family of transcription factors. 5 Although the three members share high homologies and overlapping features and activities, each protein has a unique function and has a unique, nonredundant role. 6 pRb family members are post-translationally regulated proteins. Phosphorylation of the pocket proteins is regulated in a cell-cycle dependent manner and leads to the functional inactivation of pRb, p107 or p130. [7] [8] [9] [10] [11] pRb can be also acetylated and SUMOylated but while the former modification might prevent its inactivation by phosphorylation, the function of pRb SUMOylation is still unknown. [12] [13] [14] Although acetylation of p130 has been recently demonstrated, 15 whether p107 and/or p130 undergo SUMOylation remains to be elucidated.
Small DNA tumor viruses encode oncoproteins able to regulate the functions of the pocket proteins. A characteristic feature of many of these viral oncoproteins is an LXCXE sequence motif that is necessary for high affinity binding to the pRb family members and for inhibition of pRb SUMOylation. 14, 16, 17 Kaposi's sarcoma herpesvirus (KSHV) contains two genes able to target the pRb: ORF72 that encodes a D-type cyclin that can phosphorylate pRb [18] [19] [20] [21] and ORF73 that encodes LANA1, which is able to bind pRb and neutralize E2F regulation. 22 However, these proteins do not contain the interaction domain LXCXE characteristic of tumor viruses and they cannot target p107 or p130. In this paper, we demonstrate that the KSHV latent protein LANA2, also called vIRF3, interacts with pRb, p130 and p107 in vitro and in vivo. LANA2 contains an LXCXE domain that is required for bypassing the cell growth arrest induced by reintroduction of pRb into the pRb-null SAOS-2 cell line and to inhibit pRb SUMOylation. Finally, we demonstrate, for the first time, that the pocket proteins p107 and p130 can be SUMOylated and that the LXCXE domain in LANA2 is also important to regulate their SUMOylation.
RESULTS

LANA2 interacts with pRb, p107 and p130 in vitro and in vivo
To test whether LANA2 interacted with pRb, p107 and p130 in vitro, we carried out a glutathione S-transferase (GST)-pull down assay using in vitro translated [ 35 S] methionine-labeled LANA2 protein and GST-pRb, GST-p107, GST-p130 or GST beads. LANA2 protein efficiently bound to GST-pRb, GST-p107 or GST-p130 resin but did not adhere to the GST resin (Figure 1a ), indicating that LANA2 can interact with the three pocket proteins in vitro. In order to determine whether LANA2 could also interact with the pocket proteins in vivo, we carried out co-immunoprecipitation experiments in KSHV-positive primary effusion lymphoma (PEL) cells (BCP-1). As shown in Figure 1b , LANA2 was detected in the cell extracts immunoprecipitated with anti-pRb, anti-p107 or anti-p130 antibodies. In addition, pRb, p107 and p130 were detected in the cell extracts immunoprecipitated with anti-LANA2 antibody (Figure 1b ). These results demonstrate that LANA2 expressed in KSHV-infected B cells can interact with all the three endogenous pocket proteins in vivo.
Interaction between LANA2 and pRb do not depend exclusively on the LXCXE domain In silico analysis of the LANA2 amino-acid sequence revealed that LANA2 contained a putative LXCXE motif between 109-113 aminoacid residues (LLCAE) characteristic for the interaction with the pocket proteins. Mutation of the cysteine residue has been shown to disrupt LXCXE domain function. 23, 24 In order to determine whether the interaction between LANA2 and the pocket proteins requires this motif, we generated a LANA2 construct with a C111A mutation in the LXCXE domain. Then, we carried out a GST-pull down assay using [ 35 S] methionine-labeled pRb, p107 or p130 protein and GST or increasing amounts of GST-LANA2 or GST-LANA2C111A beads. The results showed an increase in the amount of pRb, p107 or p130 bound to GST-LANA2 that correlated directly with increased levels of GST-LANA2 protein (Figure 2a ), indicating that the interaction between LANA2 and the pocket proteins is specific. In addition, we also observed that, although the LANA2C111A mutant bound pRb, p107 or p130 with slightly reduced efficiencies, there was also a specific dose-response binding (Figure 2a ). These results indicate that the LXCXE motif in LANA2 is not essential for its interaction with pRb, p107 or p130 in vitro. Then, we decided to analyze whether the LANA2 mutant in the LXCXE domain still interacted with the pocket proteins in vivo. HEK-293 cells were co-transfected with either LANA2 wild type (WT) or the mutant in the LXCXE domain together with pRb, p107 or p130, and 48 h after transfection, the cell extracts were subjected to immunoprecipitation using anti-LANA2, anti-pRb, anti-p107 or antip130 antibodies. Analysis of the immunoprecipitated extracts with either anti-LANA2 or anti-pRb antibodies revealed that both LANA2 and the LXCXE LANA2 mutant bound to pRb with similar efficiency (Figure 2b, upper panel) . However, we did not detect interaction between the LXCXE mutant of LANA2 and p107 (Figure 2b , middle panel), and we observed a clear reduction in the interaction of p130 with the mutant of LANA2 in comparison with the WT protein ( Figure 2b , lower panel). These results indicated that the LXCXE motif in LANA2 is not required for its interaction with pRb but may be important for the interaction with p107 and p130.
LANA2 inhibits the SUMOylation of pRb in an LXCXE-dependent manner pRb protein can be post-translationally modified by SUMO conjugation and this modification is negatively regulated by cellular proteins or viral oncoproteins containing the LXCXE domain.
14 As LANA2 contains an LXCXE domain, we wanted to evaluate whether LANA2 would affect SUMOylation of pRb. First, we carried out an in vitro SUMOylation assay with in vitro translated [
35 S] methionine-labeled pRb as a substrate and in the presence of GST or increasing doses of GST-LANA2. As a negative control, we performed a parallel in vitro SUMOylation assay using in vitro translated [
35 S] methionine-labeled promyelocytic leukemia (PML) protein, in the presence of GST or increasing doses of GST-LANA2. Addition of SUMO1 to the SUMOylation reaction induced the appearance of a higher molecular weight band corresponding with pRb-SUMO1 or PML-SUMO1, as expected ( Figure 3a) . Incubation of the SUMOylation reactions with LANA2 resulted in a decrease of the intensity of the pRb-SUMO1 band concomitant with increased levels of GST-LANA2 but did not cause a reduction of the intensity of the PML-SUMO1 bands (Figure 3a) , indicating that LANA2 can specifically reduce the SUMOylation of pRb in vitro. To evaluate whether LANA2 could also inhibit pRb SUMOylation in vivo, HEK-293 cells were transfected with pcDNA or Ubc9 and His6-SUMO2, in the presence or absence of LANA2, and 48 h after transfection, histidine-tagged proteins were purified. SUMOylation of endogenous pRb was then analyzed by western blot using anti-pRb antibody. As shown in Figure 3b , expression of SUMO2 led to the formation of slower migrating pRb species with an apparent molecular weight of about 130 kDa that corresponded with pRb-SUMO2 protein, as previously reported. 25 Expression of LANA2 induced a clear reduction in the levels of pRb-SUMO2 bands, indicating that LANA2 can inhibit the SUMOylation of pRb in vivo. We next analyzed whether a mutant of LANA2 in the LXCXE domain could also inhibit pRb SUMOylation. HEK-293 cells were transfected with pcDNA or Ubc9 and His6-SUMO2 and in the presence or absence of LANA2 WT or the LXCXE LANA2 mutant. Forty-eight hours after transfection, histidine-tagged proteins were purified. LANA2 can conjugate SUMO, 26 and western blot analysis of the His-purified proteins using anti-LANA2 antibody detected bands corresponding to LANA2-SUMO2 protein in the lanes corresponding to cells co-transfected with SUMO2 and LANA2 WT or the LXCXE LANA2 mutant. We then analyzed SUMOylation of endogenous pRb by western blotting using anti-pRb antibody. Transfection of SUMO2 induced the appearance of a band corresponding with pRb-SUMO2 protein that was clearly reduced in the presence of WT LANA2 (Figure 3c ), reinforcing our previous observation. However, we did not observe a clear reduction of pRb SUMOylation after expression of the LANA2 mutant in the LXCXE domain. All together these results demonstrated that LANA2 inhibits pRb SUMOylation in an LXCXE-dependent manner.
LANA2 blocks the cell growth arrest mediated by pRb in an LXCXE-dependent manner One of the most relevant abilities of the pocket proteins is to control the cell cycle by negative modulation of the transition between the G1 and S phases. [27] [28] [29] [30] Our results indicated that the LXCXE domain in LANA2 was not required for interacting with pRb but it was essential to inhibit pRb SUMOylation. We then sought to determine the consequences of the interaction between LANA2 and pRb and the role of the LXCXE motif on the LANA2 effect. pRb expression in SAOS-2 cells has been shown to induce cell growth arrest. Thus, SAOS-2 cells were co-transfected with green fluorescent protein (GFP) and pcDNA or pRb in the presence or absence of LANA2 WT or LANA2C111A, and at 48 h after transfection, the DNA content of the GFP-positive cells was determined by analytical flow cytometry. As expected, reintroduction of pRb in SAOS-2 cells induced a G1 cell-cycle arrest that was reversed after transfection of LANA2 WT but not the LANA2C111A mutant (Figure 4a ). In addition, SAOS-2 cells were transfected with pcDNA or co-transfected with pcDNA-pRb and pcDNA, pcDNA-LANA2 WT or pcDNA-LANA2C111A, selected with G418 for 2 weeks, and then the number of antibiotic-resistant colonies was counted. Introduction of pRb into the pRb-null SAOS-2 cells resulted in a decrease in the number of colonies compared with pcDNA. Similarly, co-transfection of LANA2 WT but not the LANA2C111A mutant significantly increased the number of antibiotic-resistant colonies (Figure 4b ). These results indicate that LANA2 neutralize the growth inhibitory effect of pRb in an LXCXE-dependent manner.
Both p107 and p130 can be SUMOylated, a modification that can be inhibited by LANA2 in an LXCXE-dependent manner We then decided to evaluate whether the pocket proteins p107 or p130 could be also modified by SUMO. It is known that most SUMOylated proteins interact directly with the E2 SUMO conjugating enzyme Ubc9. 31 Then, we first evaluated the putative interaction between p107 or p130 and Ubc9. HEK-293 cells were co-transfected with a plasmid encoding p107 or p130 and Ubc9-SV5, and 48 h after transfection, protein extracts were incubated with either anti-SV5 or a control antibody. Inmunoprecipitated proteins were then analyzed by western blotting using anti-p107 or anti-p130 antibodies. As shown in Figure 5a , both p107 and p130 were detected in the protein extracts immunoprecipitated with anti-SV5 antibody but not in those immunoprecipitated with control antibody. These results indicated that p107 and p130 interact in vivo with Ubc9. We next evaluated the SUMO modification of p107 or p130 in a reconstituted in vitro system, where in vitro-translated [
35 S] methionine-labeled p107 or p130 protein was incubated with SUMO1 or SUMO2 in the presence of the recombinant SUMOylation machinery. As shown in Figure 5b , addition of SUMO1 or SUMO2 to the p107 in vitro SUMOylation reaction led to the appearance of additional higher molecular weight bands, indicating that p107 can be SUMOylated in vitro. To further confirm that these bands corresponded with SUMOylated protein, p107-SUMO1 and p107-SUMO2 proteins obtained as described above were incubated in the presence of GST-SENP1 in an in vitro deSUMOylation reaction. The p107-SUMO1 and p107-SUMO2 bands disappeared after incubation with SENP1 (Figure 5b ), confirming that p107 is SUMOylated in vitro. Similarly, incubation of p130 with SUMO1 or SUMO2 resulted in a smear of additional higher molecular weight bands that disappeared after incubation with SENP1, indicating that p130 is SUMOylated in vitro (Figure 5b) . Then, we decided to evaluate whether p107 and p130 could be also SUMOylated in vivo. HEK-293 cells were transfected with p107 or p130 and pcDNA or Ubc9 and His6-SUMO2, and 48 h after transfection, histidine-purified proteins were analyzed using anti-p107 or anti-p130 antibodies. Consistent with our in vitro data, transfection of SUMO2 resulted in higher molecular weight bands that corresponded to p107-SUMO2 or p130-SUMO2 conjugates (Figure 5c ), indicating both p107 and p130 pocket proteins can be also SUMOylated in vivo. Then, we decided to evaluate whether LANA2 could also repress the SUMOylation of p107 or p130. HEK-293 cells were transfected with p107 or p130 and pcDNA or Ubc9 and His6-SUMO2, in the presence or absence of LANA2. Forty-eight hours after transfection, histidine-tagged purified proteins were analyzed by western blot using anti-LANA2 and anti-p107 or anti-p130 antibodies. Western blot analysis using anti-LANA2 antibody detected bands corresponding to LANA2-SUMO2 protein in the lanes corresponding to cells co-transfected with SUMO2 and LANA2 WT or the LXCXE LANA2 mutant. Bands corresponding with p107-SUMO2 or p130-SUMO2 proteins were detected in those cells transfected with Ubc9 and SUMO2, as previously observed (Figure 5d ). Expression of LANA2 WT resulted in a clear reduction in the intensity of the p107-SUMO2-or p130-SUMO2-modified bands that was not observed after expression of the mutant in the LXCXE domain, indicating that LANA2 partially inhibits the SUMOylation of p107 and p130 in an LXCXE-dependent manner (Figure 5d ).
DISCUSSION
The retinoblastoma family of proteins represents key molecules in tumor suppression. Irrespective of their structural and biochemical similarities, each pocket protein has a unique function and has a unique, non-redundant role. 27 Many of the sequence similarities reside in a homologous functional domain known as the pocket region that is responsible for the interaction with cellular proteins and oncoproteins from DNA tumor viruses. 17, 32 A characteristic feature of many viral and cellular proteins that target the pocket proteins is the presence of a short LXCXE sequence motif, which binds to a hydrophobic grove in the B domain of the pocket. 16, 17 KSHV encodes two latent proteins, LANA and vCyc, which target the pRb. 19, 21, 22 However, to date, no KSHV proteins able to target the other pocket proteins p107 and p130 have been described. Here we demonstrate that the latent protein LANA2 is able to interact with all the three pocket proteins pRb, p107 and p130 both in vitro and in KSHV-infected PEL cells. In addition, we show that LANA2 inhibits the cell growth arrest mediated by pRb in an LXCXE-dependent manner; however, mutation of this motif in LANA2 did not abolish the interaction of LANA2 with pRb, indicating that the interaction between LANA2 and pRb does not depend on the LXCXE motif. The interaction between pRb and cellular proteins containing an LXCXE motif sometimes does not require this domain as it has been reported for BCRA1. 33 Furthermore, the interaction of viral oncoproteins containing LXCXE domains through additional regions has been previously reported. Thus, the interaction between pRb and adenovirus E1A or polyomavirus SV40 large T antigen is mediated not only by an LXCXE domain but also by additional regions. [34] [35] [36] [37] All of the three pocket proteins can be regulated at the posttranslational level. pRb is regulated by phosphorylation, acetylation and SUMOylation. 12 SUMOylation targets a specific residue in the lysine cluster of the pocket B region of pRb, preferentially modifies the hypophosphorylated form of pRb and requires the integrity of the pocket domain.
14 Although the consequences of pRb SUMOylation are not clear, it is known that the level of pRb SUMOylation is controlled by the interaction of pRb with viral and cellular proteins harboring the LXCXE-motif.
14 LANA2 reduced SUMOylation of pRb in an LXCXE-dependent manner, confirming again the functionality of this domain. Both p107 and p130 proteins are also regulated by phosphorylation, but while p130 can be also acetylated, 15 no acetylation of p107 has been reported, and so far no SUMOylation of p107 or p130 has been demonstrated. The SUMOylation of pRb led us to evaluate the putative SUMOylation of p107 and p130. A significant fraction of the proteins that are modified by SUMO interact directly with the E2 SUMO conjugation enzyme, Ubc9. 31 Our results demonstrate that both p107 and p130 interact with Ubc9, pointing to these two proteins as putative SUMO targets. Indeed, we demonstrated that both p107 and p130 proteins can be SUMOylated in vitro and in vivo. Furthermore, LANA2 expression was also able to inhibit p107 and p130 SUMOylation, an effect that was clearly reduced after expression of the LXCXE LANA2 mutant. All together these results indicate that LANA2 inhibits the SUMOylation of the three pocket proteins in an LXCXE-dependent manner. The functions of pRb SUMOylation are not clear, but it has been suggested that conjugation of SUMO2 to pRb may have a role in premature senescence 25 and that inhibition of pRb SUMOylation by oncoviral proteins may represent a strategy used by virus to suppress cell senescence. Further work on the activities of p107 or p130-SUMO proteins will help us to evaluate the consequences of the inhibition of SUMOylation of the pocket proteins by viral oncoproteins.
Targeting of all pRb family members by LANA2 could be seen as a viral need for blocking a redundant function of the pocket proteins, for instance, the imposition of G1/S arrest. In addition to its role on the cell cycle, LANA2 might also inhibit apoptosis by targeting Rb. [38] [39] [40] [41] [42] [43] Several reports evidence the multiple antiapoptotic and pro-proliferative activities of LANA2. Thus, for example, LANA2 inhibits the transcriptional activation and apoptosis mediated by p53, 44 inhibits the apoptosis mediated by the double-stranded RNA-dependent protein kinase R, 45 interferes with the PML-mediated transcriptional repression of survivin, 46 enhances hypoxia-inducible factor-1-alpha-mediated Figure 5 . Both p107 and p130 undergo SUMO modification, and LANA2 inhibits its SUMOylation in an LXCXE-dependent manner. (a) Both p107 and p130 interact with Ubc9 in vivo. p107 or p130 are detected in Ubc9-SV5 immunoprecipitates (IPs) from HEK-293 cells co-transfected with Ubc9-SV5 and p107 or p130, respectively, by western blotting (WB). By contrast, control IPs using an irrelevant mouse monoclonal antibody yielded no p107 or p130 bands. (b) Both p107 and p130 are SUMOylated in vitro. In vitro-translated [ 35 S]-labeled p107 or p130 were subjected to in vitro SUMOylation assay in the presence of SUMO1 or SUMO2. SUMO-conjugated p107 and p130 proteins were then incubated with GST or GST-SENP1 as described in Materials and Methods. Proteins were resolved by SDS-PAGE and visualized by autoradiography. (c) Both p107 and p130 are SUMOylated in vivo. HEK-293 cells were transfected with p107 or p130 and pcDNA or Ubc9 and His6-SUMO2. Whole protein extracts or histidine-tagged purified proteins were analyzed by western blot using anti-p107 or p130 antibodies. (d) LANA2 inhibits the SUMOylation of p107 or p130 in a LXCXE-dependent manner. HEK-293 cells were transfected with p107 or p130 and pcDNA or Ubc9 and His6-SUMO2, in the presence or absence of LANA2 WT or LANA2C111A, as indicated. Lysates and histidine-SUMO conjugates recovered from Niquel-agarose beads were separated by SDS-PAGE and probed with anti-LANA2, anti-p107 or anti-p130 antibodies. Note that unmodified p107 and p130 proteins bind nonspecifically to the nickel beads.
cell proliferation, 47 increases c-Myc signaling, 48, 49 inhibits nuclear factor-kB activation 50 and interferon transcription and production. [51] [52] [53] The ability of LANA2 to target the pocket proteins together with its additional activities might then account for the reduction of proliferation and apoptosis detected in PEL cells in response to downmodulation of LANA2 levels. 54 Moreover, several lines of research suggest that the simultaneous inactivation of all the three pRb family members may be necessary to manifest the fully transformed phenotype of mammalian cells, 37, [55] [56] [57] suggesting that targeting of the pocket proteins might have important implications for the oncogenic activity of LANA2.
In addition to overlapping functions, p107 and p130 could have specific activities with important consequences for KSHV infection. In this regard, p107, but not pRb, itself can directly bind c-Myc and prevent its transactivation. 58, 59 LANA2 has been shown to stabilize and induce the transactivation of c-Myc, in part, by its association with the transcriptional co-factor for c-myc, Skp2 or by inhibiting the association between c-Myc-suppressor MM-1 alpha and c-Myc. 48, 49 It is then tempting to speculate that the interaction of LANA2 with p107 may also contribute to the transcriptional activation of c-Myc.
KSHV establishes a long-term latent infection in B lymphocytes, and the regulation of reactivation of the lytic cycle from latency is considered to be controlled, at least in part, through epigenetic factors. 60, 61 In this sense, the upregulation of the levels of DNA methyltransferase-3a and -3b induced as a consequence of the downmodulation of p130 by the KSHV miRNA K12-4-5p has been suggested to contribute to maintain the latent state of the KSHV genome. 62, 63 Based on these data, we speculate that LANA2 could also help establish viral latency by targeting the pocket proteins.
In summary, the inhibition of the pocket proteins might help LANA2 to create a cellular environment supportive of DNA replication and could contribute to the establishment of viral latency. This work enlarges the list of viral proteins capable of interacting with the pocket proteins through an LXCXE domain, and the list of KSHV proteins with the capacity to interact with pRb. Furthermore, this is the first example of a KSHV protein that can modulate the SUMOylation of the pocket proteins. Although the classical tumor-suppressor proteins are often mutated in human cancers, pRb is not mutated in KSHV-associated malignancies. 64 Furthermore, p130 is infrequently mutated, and no p107 mutations in human cancers have been identified. [65] [66] [67] [68] [69] Thus, modulation of their activities by post-translational mechanisms provides a new mechanism by which LANA2 could contribute to KSHV pathogenesis.
MATERIALS AND METHODS
Cell lines
The human osteosarcoma cell line SAOS-2 and the human embryonic kidney cell line HEK-293 were grown in Dulbecco's modified Eagle medium (Gibco BRL, Madrid, Spain) supplemented with 10% fetal bovine serum, penicillin (100 units/ml), streptomycin (100 mg/ml) and 2 mM L-glutamine. BCP-1 PEL cells were grown in RPMI supplemented with 20% fetal calf serum, glutamine and penicillin-streptomycin. Transfection of HEK-293 cells was done using Xtreme (Roche, Madrid, Spain) following the manufacturer's instructions. In all, 1 Â 10 6 SAOS-2 cells were transfected by electroporation, using a Bio-Rad Gene Pulser at 250 mV constant current (Bio-Rad Laboratories SA, Madrid, Spain).
Plasmids
Plasmids pcDNA-LANA2 and GST-LANA2 have been previously described. 44 Plasmids pcDNA-LANA2C111A and GST-LANA2C111A were generated using the QuickChange PCR-based mutagenesis kit (Stratagene, La Jolla, CA, USA) and the pcDNA-LANA2 and GST-LANA2 plasmids as template, respectively. Oligonucleotides used in the site-directed mutagenesis are LANA2C111AF: 5 0 -GGAATTCATGGCGGGACGCAGGCTTACCTGG-3 0 and LANA2C111AR: 5 0 -GGGATCCGGTCATCACATGTAACTGAACG-3 0 . Plasmids pcDNA-pRb, pcDNA-p107 and pcDNA-p130 were a generous gift of Anxo Vidal (University of Santiago de Compostela, Spain). pcDNA-His6-SUMO1, pcDNA-His6-SUMO2 and pcDNA-Ubc9-SV5 plasmids have been previously described. [70] [71] [72] GST pull-down GST-pull down experiments were performed using [ 35 S]methionine-labeled in vitro transcribed/translated LANA2, pRb, p107 or p130 proteins and GST, GST-pRb, GST-p107, GST-p130, GST-LANA2 or GST-LANA2C111A, as described previously. 46 In vitro transcription/translation of proteins were performed using 1 mg of plasmid DNA and rabbit reticulocyte-coupled transcription/translation system according to the instructions provided by the manufacturer (Promega, Madrid, Spain).
In vitro SUMO conjugation assay
In vitro SUMO conjugation assay was performed on [ 35 S]methioninelabeled in vitro transcribed/translated pRb, p107 or p130 proteins as described previously 73 using recombinant E1 (Biomol, Enzo Life Sciences, Lausen, Switzerland), Ubc9 and SUMO1 or SUMO2.
In vitro deSUMOylation assay p107-SUMO1, p107-SUMO2, p130-SUMO1 or p130-SUMO2 proteins obtained in an in vitro SUMOylation reaction as described above was incubated with 2 mg of GST-SENP1 (Biomol) in 30 ml reaction buffer containing 50 mM Tris (pH 7.5), 2 mM MgCl 2 and 5 mM b-mercaptoethanol. Reactions were incubated at 37 1C for 1 h and terminated with sodium dodecyl sulfate (SDS) sample buffer containing mercaptoethanol. Reactions products were then fractionated by SDS-PAGE (polyacrylamide gel electrophoresis) and detected by autoradiography.
Purification of His-tagged conjugates
Purification of His-tagged conjugates using Ni2 þ -NTA-agarose beads was performed as described. 46 
Western blot and immunoprecipitation analysis and antibodies
For western blot analysis, cells were washed in phosphate-buffered saline, scraped in SDS-PAGE loading buffer and boiled for 5 min. Proteins of total extracts were separated by 8% SDS-PAGE and transferred to nitrocellulose membrane. For immunoprecipitation analysis, cells were washed in phosphate-buffered saline and then lysed in RIPA buffer containing fresh proteinase inhibitor mixture. After a brief sonication, the lysates were cleared by high-speed centrifugation. A 50% protein A-sepharose slurry, which had been incubated with the appropriate antibody at 4 1C overnight, was added to the cleared lysates and incubated at 4 1C for 2 h. Afterwards, the sepharose beads were collected and washed five times in RIPA buffer. The precipitated protein complexes were recovered by boiling them in SDS sample buffer and analyzed by western blotting. Western blotting was carried out using standard methods. All antibodies were used at a dilution of 1:1000 of the stock in blocking buffer (5% skim milk prepared in 1 Â TBS-Tween). The following antibodies were used: antip107 (sc-318, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p130 (sc-317, Santa Cruz Biotechnology), anti-pRb (554136, BD Pharmigen, BD Biosciences, Madrid, Spain), anti-LANA2 (NB200-167, Novus Biologicals, Cambridge, UK) and anti-alpha-tubulin antibody (MCA78G, Serotec, Dü sseldorf, Germany).
Colony-formation assays SAOS-2 cells were transfected with the indicated expression vectors. All the transfections were performed using the same amount of plasmids carrying G-418 resistance. G-418 selection was initiated 2 days after transfection, dishes were stained with crystal violet 14 days later and colonies exhibiting G-418 resistance were counted.
Cell-cycle analysis SAOS-2 cells in 10 mm dishes were transfected with GFP and the indicated plasmids, and 48 h after transfection, cells were harvested, fixed and stained by using propidium iodine. The distribution of GFP-positive cells in the different phases of the cell cycle was determined by analytical flow cytometry using a CYAN (DAKO Cytomation, Glostrup, Denmark), and data were analyzed by using Summit software (DAKO Cytomation).
